Skip to main content
drug protocol number
CQAW039A2315
drug sponsor
Novartis
drug study
QAW039/Fevipiprant
drug trial site
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
drug status
Ongoing
drug phase